CD19 and lymphoma: Since then, several CAR-T cell therapies (CD19-targeted brexucabtagene autoleucel - Tecartus®, lisocabtagene maraleucel - Breyanzi®, and B cell maturation antigen-targeted idecabtagene vicleucel - Abecma®, ciltacabtagene autoleucel - Carvykti®) have been approved by the FDA for the treatment of hematological malignancies, including lymphomas and some forms of leukemia, and most recently for the treatment of multiple myeloma [14,15,16].